Latest Updates in Healthcare: Special Research on Agios, Akebia, Akers, Akorn, and Albany

NEW YORK, February 3, 2015 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Agios (NASDAQ: AGIO), Akebia (NASDAQ: AKBA), Akers (NASDAQ: AKER), Akorn (NASDAQ: AKRX), and Albany (NASDAQ: AMRI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

AGIO Research Report: ( http://get.analystsreview.com/pdf/?c=Agios&d=03-Feb-2015&s=AGIO ),

AKBA Research Report: ( http://get.analystsreview.com/pdf/?c=Akebia&d=03-Feb-2015&s=AKBA ),

AKER Research Report: ( http://get.analystsreview.com/pdf/?c=Akers&d=03-Feb-2015&s=AKER ),

AKRX Research Report: ( http://get.analystsreview.com/pdf/?c=Akorn&d=03-Feb-2015&s=AKRX ),

AMRI Research Report: ( http://get.analystsreview.com/pdf/?c=Albany&d=03-Feb-2015&s=AMRI ).

============

--

Analyst Update: Strategic Agreements, Clinical Trial Updates,Patent Protection, FDA Approval, and New Contract

Reviewed by: Rohit Tuli, CFA®  

The U.S. stocks ended higher on Monday helped by a late-session rally in the energy shares which also offset a fresh set of disappointing economic data. The Dow Jones Industrial Average rose 1.14% to close at 17,361.04, the S&P 500 increased 1.30% to close at 2,020.85, and the Nasdaq Composite gained 0.89% to end at 4,676.69. Energy shares led the advance, with the S&P 500 energy sector ending up nearly 3% following rise in the crude oil prices. Disappointing data on consumer spending and the manufacturing sector released on Monday weighed on the market early in the session. The European stocks ended on a mixed note on Monday amid continued uncertainty over Greece's debt negotiations and rising worries over the health of global economies. The pan-European Euro Stoxx 600 Index closed largely flat. In Asia, markets were mostly under pressure after fresh data raised concerns over China's manufacturing sector.

Agios Pharmaceuticals, Inc. (Agios) announced that its cancer drug development collaboration partner Celgene Corporation (Celgene) has agreed to exercise its option to obtain an exclusive license outside the United States for AG-120, a first-in-class, oral, potent inhibitor of the mutant IDH1 protein.

Akebia Therapeutics, Inc. (Akebia) announced that it has completed enrollment ahead of schedule in the original two cohorts of its Phase 2 clinical study evaluating AKB-6548 in patients with anemia related to chronic kidney disease (CKD) who are undergoing dialysis.

Akers Biosciences, Inc. (Akers) announced that its Rapid Blood Separation Technology has been granted patent protection in Europe. Akers, which received U.S. patent protection for the Technology in 2011, said that it is now actively looking for commercialization partners and licensees in both Europe and the U.S.

Akorn, Inc. (Akorn) announced that its ophthalmic phenylephrine product will be re-launched shortly in the market as the Company has received U.S. Food and Drug Administration's (FDA) approval.

Albany Molecular Research, Inc. (Albany) announced that it has received a 10-year federal contract worth up to $37 million from the National Institutes of Health (NIH) for drug development and manufacturing services.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

 


SOURCE Analysts Review

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.